STAT+: FTC warns drugmakers they can face legal action over improper patent listings
STAT
SEPTEMBER 14, 2023
In explaining its new policy statement , the FTC noted that some drug companies have failed to follow requirements for listing patents in the so-called Orange Book in hopes of thwarting competition from lower-cost generic medicines.
Let's personalize your content